Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Parasitic organism or component thereof or substance...
Patent
1993-11-16
1995-03-07
Nucker, Christine M.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Parasitic organism or component thereof or substance...
4241911, 4241921, 4242691, 435 693, 435 697, 530402, 530403, 530806, A61K 39015, C07K 1508
Patent
active
053956141
ABSTRACT:
Protective Plasmodium falciparum hybrid proteins which contain part-sequences of the malaria antigens HRPII and SERP, the preparation and use thereof.
The invention relates to hybrid proteins composed of part-sequences of the malaria antigens HRPII and SERP. The HRPII sequence has already proven protective in the monkey model (EP-A2-0 315 085), where a C-terminal region of 189 amino acids has been used in the present invention in the same way as in the preceding protection experiment. SERP was identified with the aid of an antiserum against a protective protein band (EP-A1-0 283 882); the part-sequence used (amino acids (AA) 631-892 or 630-764) contains at least two T-cell epitopes (Roussilhon et al. (1990), Immunol. Letters 25, 149-154). In preferred embodiments, further T-cell epitope-containing regions of other P. falciparum proteins such as merozoite surface antigen I (MSA I or else "195 kd antigen"), amino acids from 100 to 300, are incorporated (Crisanti et al. (1988), Science 240, 324-326). The property common to all the hybrid components is that they represent highly conserved peptide sequences. Protection against a malaria infection is generated by immunization with abovementioned hybrid proteins.
REFERENCES:
patent: 4859465 (1989-08-01), Rutter
patent: 4957738 (1990-09-01), Patarroyo
patent: 5130416 (1992-07-01), Wellems
Cox, F. E. G., TIBTECH 9:389-394 (Nov., 1991), "Malaria vaccines--progress and problems".
Crisanti, A., et al., Science 240:1324-1326 (3 Jun. 1988), "Epitopes recognized by ells map within the conserved part of the GP190 of P. falciparum".
Groux, H., et al., Eur. J. Immunol. 20:2317-2323 (1990), "Functional characterization of the antibody-mediated protection against blood stages of Plasmodium falciparum in the monkey Saimiri sciureus".
Herrera, S., et al., P.N.A.S. (USA) 87:4017-4021 (May, 1990), "Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins".
Knapp, B., et al., Mol. Biochem. Parasitol. 32:73-84 (1989), "Molecular cloning, genomic structure and localization in a blood stage antigen of Plasmodium falciparum characterized by a serine stretch".
Knapp, B., et al., Behring Inst. Mitt. 88:147-156 (Feb., 1991), "A recombinant hybrid protein as antigen for an anti-blood stage malaria vaccine".
Mitchell, G. H., Parasitol. 98:S29-S47 (1989), "An update on candidate malaria vaccines".
Odink, K. G., et al., FEBS Lett. 173(1):108-112 (1984), "Expression of cloned cDNA for a major surface antigen of Plasmodium falciparum merozoites".
Phillips, R. E.; et al., Perasitology Today 2(10):271-282 (1986) "The Pathophysiology of Severe falciparum malaria".
Wellems, T. E., et al., P.N.A.S. (USA) 83:6065-6069 (Aug., 1986), "Homologous genes encode two distinct histidine-rich proteins in a cloned isolate of Plasmodium falciparum".
Knapp, B. et al., "A Recombinant Hybrid Proteins as Antigen Foran Anti-Blood Stage Malaria Vaccine", 4th Intl. Erlangen Workshop on Molecular Aspects of Immunological Host-Parasite Interactions, Erlangen, Germany, Sep. 27-29, 1990.
Cox, F. E. G., (1991), Trends in Biotech., 9:389-394.
Knapp, B. et al., (1989), Med. Biochem. Parasitol. 32:73-84.
Herrera, S. et al., (1990), Proc. Natl. Acad. Sci. USA 87:4017-4021.
Remaut, E. et al., (1981), Gene 15:81-93.
Holder, A. M. et al., (1988), Parasitology 97:373-382.
B. Knapp et al., Behring Inst. Mitt. 88:147-156 (1991).
C. Roussilhon et al., Immunology Letters, 25:149-154 (1990).
A. Crissanti et al., Science 240:1324-1326 (1988).
T. Wellems et al., PNAS USA 83:6065-6069 (Aug. 1986).
Responses Of T Cells From Sensitized Donors To Recombonant And Synthetic Peptides Corresponding To Sequences Of The Plasmodium falciparum SERP Antigen, Rousilnon et al., Imunol. Letters 25, 149-154 (1990).
Epitopes Recognized By Human T Cells Map Within The Conserved Part Of The GP190 Of P. falciparum, Crisanti et al., Science 240, 324-326 (1988).
Characterization Of Foot-And-Mouth Diseases Virus Gene Products With Antisera Against Bacterially Synthesized Fusion Proteins, Strebel et al., J. Virol. 57, 893-991 (1986).
Tightly Regulated Tac Promoter Vectors Useful For The Expression Of Unfused Proteins In Escherichia coli, Aman et al., Gene 69, 301-315 (1988).
A Histidine Alanine Rich Recombinant Antigen Protects Aotus Monkeys From P. falciparum Infection, Knapp et al., Behring Inst. Mtt. 82, 349-359 (1988).
Molecular Cloning: A Laboratory Manual, 2nd. Edn., Sambrook et al., Cold Spring Harbor Laboratory Press, (1989).
Malarial Proteinase?, Higgins et al., Nature 340, 604 (1989).
Engineering Hybrid Genes Without The Use Of Restriction Enzymes: Gene Splicing By Overlap Extension, Horton et al., Gene 77, 61-68 (1989).
Enders Burkhard
Hundt Erika
Knapp Bernhard
Kupper Hans
Behringwerke Aktiengesellschaft
Cunningham Thomas
Nucker Christine M.
LandOfFree
Protective Plasmodium falciparum hybrid proteins which contain p does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protective Plasmodium falciparum hybrid proteins which contain p, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protective Plasmodium falciparum hybrid proteins which contain p will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1404663